Healthcare DLT in Switzerland: Patient Data, Clinical Trials, and Pharmaceutical Integrity
Switzerland’s healthcare ecosystem — encompassing world-class hospitals, major pharmaceutical companies, leading medical device manufacturers, and a sophisticated health insurance system — presents distinctive opportunities for distributed ledger technology adoption. The convergence of stringent data protection requirements, complex multi-stakeholder coordination needs, and a culture of precision and quality creates an environment where DLT’s properties of immutability, transparency, and programmable trust can deliver substantial value across the healthcare value chain.
Patient Data Sovereignty
The management of patient health data is one of the most compelling — and most challenging — applications of DLT in Swiss healthcare. Switzerland’s electronic patient dossier (EPD) system, mandated by the Federal Act on the Electronic Patient Dossier (EPDG), establishes a framework for the digital storage and sharing of patient health information across healthcare providers. DLT-based approaches to patient data management offer potential enhancements to this framework, particularly in the areas of data sovereignty, consent management, and interoperability.
In a DLT-based patient data model, the patient retains control over their health data through a self-sovereign identity framework. Rather than storing health records in centralised databases controlled by individual healthcare providers, the DLT approach records access permissions and consent directives on the ledger, enabling patients to grant and revoke access to their data on a provider-by-provider and record-by-record basis. The actual health data may be stored off-chain in encrypted form, with the ledger maintaining a secure index of where data is stored and who has permission to access it.
This model addresses several shortcomings of traditional health data management. Data portability — the ability of patients to transfer their health records between providers — is facilitated by the shared access control layer on the ledger. Consent management is made transparent and auditable, with every access grant, revocation, and data retrieval recorded on the immutable ledger. Data integrity is assured by cryptographic hashing, which ensures that any unauthorised modification of health records is detectable.
The data protection requirements of the Swiss FADP and the EU GDPR (which applies to Swiss healthcare providers serving EU patients) create specific constraints on the use of DLT for health data. The right to erasure, the right to data portability, and the requirements for data minimisation and purpose limitation must be carefully navigated in the DLT context. Swiss healthcare DLT implementations typically address these requirements through off-chain data storage with on-chain access control, ensuring that personal health data can be deleted from the off-chain storage even though the corresponding access control records on the ledger remain immutable.
Clinical Trial Management
The management of clinical trials is a data-intensive, multi-stakeholder process that involves pharmaceutical companies, clinical research organisations (CROs), hospital sites, regulatory authorities, ethics committees, and patients. DLT offers potential improvements in several aspects of clinical trial management, from protocol adherence monitoring to data integrity assurance and regulatory submission.
Clinical trial data integrity is a critical concern for regulators and pharmaceutical companies. The credibility of trial results depends on the assurance that data has been collected, recorded, and analysed according to the approved protocol, without selective reporting or retrospective modification. DLT provides an immutable audit trail of trial data, recording when data was entered, by whom, and whether any modifications were made. This tamper-evident record strengthens the evidentiary value of clinical trial data and facilitates regulatory review.
Informed consent management in clinical trials is another area where DLT adds value. The consent process — in which patients are informed about the trial, its risks and benefits, and their rights — is legally and ethically fundamental to clinical research. DLT-based consent management creates an immutable record of when consent was given, what information was provided to the patient, and whether consent was subsequently withdrawn. This record facilitates compliance with ethical review requirements and provides a robust audit trail for regulatory inspections.
The coordination of clinical trial supplies — investigational medicinal products (IMPs), laboratory kits, and patient materials — involves complex logistics that span multiple countries and regulatory jurisdictions. DLT-based supply chain tracking, integrated with the trial management platform, provides real-time visibility into the location, condition, and status of trial supplies, enabling proactive management of supply disruptions and ensuring compliance with good distribution practice (GDP) requirements.
Swiss pharmaceutical companies, including Novartis and Roche, have participated in industry initiatives exploring DLT for clinical trial management. These initiatives typically focus on specific elements of the trial lifecycle — such as consent management or data integrity — rather than attempting to build comprehensive DLT-based trial management platforms, reflecting the incremental approach that characterises institutional DLT adoption in regulated industries.
Drug Supply Chain Integrity
The pharmaceutical supply chain, from active pharmaceutical ingredient (API) manufacturing through formulation, packaging, distribution, and dispensing, presents multiple points at which DLT can enhance integrity, traceability, and regulatory compliance.
Serialisation — the assignment of unique identifiers to individual drug packages — is a regulatory requirement in many jurisdictions, including the EU (under the Falsified Medicines Directive) and Switzerland. DLT-based serialisation systems provide an immutable record of each product unit’s journey through the supply chain, enabling point-of-dispensing verification that the product is genuine and has not been diverted, tampered with, or counterfeited.
For a broader discussion of pharmaceutical supply chain DLT applications, see our analysis of supply chain DLT in Switzerland.
Temperature-sensitive pharmaceutical products require cold chain management that ensures continuous maintenance of specified temperature ranges. DLT integrated with IoT sensors creates an automated, tamper-resistant record of temperature compliance throughout the distribution chain. Excursions are immediately visible to all authorised parties, enabling rapid response and regulatory reporting.
The tracking of controlled substances — narcotics, psychotropic drugs, and precursor chemicals — is subject to stringent regulatory requirements under the Swiss Narcotics Act and international conventions. DLT-based tracking of controlled substances provides an immutable audit trail of every transaction in the supply chain, from manufacture to dispensing, facilitating compliance with reporting requirements and enabling the detection of diversion or theft.
Medical Device Traceability
Switzerland’s medical device industry, which includes global companies such as Straumann, Sonova, and numerous specialist manufacturers, faces increasing regulatory requirements for device traceability. The EU Medical Device Regulation (MDR) and the Swiss Medical Devices Ordinance (MedDO) require manufacturers to implement unique device identification (UDI) systems that enable the tracing of devices from manufacture through distribution to the patient.
DLT-based UDI systems provide an immutable record of each device’s manufacturing history, quality certifications, distribution path, and implantation or deployment. For implantable devices, DLT-based traceability enables rapid identification and notification of affected patients in the event of a safety alert or recall, significantly improving the speed and completeness of patient notification compared to traditional paper-based systems.
Health Insurance and Claims
Switzerland’s mandatory health insurance system, administered by competing health insurers (Krankenkassen) under the Health Insurance Act (KVG), involves complex claims processing workflows that could benefit from DLT-based automation. The exchange of claims data between healthcare providers and insurers, the verification of coverage, and the processing of payments involve multiple parties and multiple data formats, creating inefficiencies and opportunities for error or fraud.
DLT-based claims processing for health insurance could automate the verification of coverage, the matching of claims against policy terms, and the calculation and processing of payments. Smart contracts could encode the coverage rules specified by the KVG and supplementary insurance policies, enabling automated adjudication of routine claims while flagging exceptional cases for manual review.
The fraud detection capabilities of DLT are also relevant to the Swiss health insurance market. The immutable audit trail of claims data, combined with pattern analysis across multiple insurers (in a privacy-preserving consortium model), could enhance the detection of fraudulent claims that cost the Swiss healthcare system hundreds of millions of francs annually.
Regulatory Considerations
Healthcare DLT applications in Switzerland must navigate a regulatory landscape that includes health law, data protection law, medical device regulation, pharmaceutical law, and insurance regulation. The multiplicity of regulatory frameworks reflects the complexity of the healthcare sector and creates compliance challenges for DLT implementers.
Swissmedic, the Swiss Agency for Therapeutic Products, has engaged with the potential of DLT for pharmaceutical supply chain integrity and clinical trial data management, though specific guidance on DLT adoption has been limited. The agency’s technology-neutral approach to regulation means that DLT-based systems must meet the same requirements as conventional systems in terms of data integrity, security, and regulatory reporting.
The cantonal nature of Swiss healthcare regulation — with hospitals, pharmacies, and healthcare providers subject to cantonal as well as federal regulation — adds a layer of complexity for DLT implementations that span multiple cantons. Interoperability between cantonal systems and compliance with potentially divergent cantonal requirements must be addressed in the design of healthcare DLT platforms.
Outlook
The adoption of DLT in Swiss healthcare is at an earlier stage than in financial services or supply chain management, reflecting the sector’s conservative approach to technology adoption, the sensitivity of health data, and the complexity of the regulatory environment. However, the convergence of regulatory pressure (for supply chain transparency, data integrity, and patient data sovereignty), technological maturation, and demonstrated value in adjacent sectors is creating momentum for broader healthcare DLT adoption.
The path forward is likely to be incremental, with DLT solutions adopted for specific, well-defined use cases — pharmaceutical serialisation, clinical trial consent management, medical device traceability — before expanding to broader applications. Switzerland’s combination of healthcare excellence, pharmaceutical industry presence, and DLT innovation capability positions it well to lead this cautious but consequential transformation.
For related coverage, see our analysis of DLT identity solutions and privacy-preserving DLT.
Donovan Vanderbilt is a contributing editor at ZUG DLT, covering distributed ledger technology law, regulation, and institutional adoption from Zurich. The Vanderbilt Portfolio AG provides research and analysis on Swiss digital asset infrastructure.